Skip to content
OpenCapital
Get started

Inhibrx Biosciences, Inc. INBX Q1 2026 earnings

Reported May 14, 2026 · Before market open

Diluted EPS-$2.15Beat by $0.22
EPS estimate-$2.37

Next report

Aug 12, 2026 (in a month)
EPS estimate-$2.28

Financials

Q1 2026

Income statement

See full
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$1.52B+385%
Enterprise value$1.54B+982%

Returns & leverage

See full
Current ratio6.5×+1.3×

Versus estimates

Revenue

Q2 2025$1.3MQ4 2024$100.0K

Diluted EPS

Q1 2026-$2.15Beat by $0.22
Q4 2025-$2.11Miss by $0.03Q3 2025-$2.28Miss by $0.20Q2 2025-$1.85Beat by $1.07Q1 2025-$2.80Miss by $0.25Q4 2024-$3.09Miss by $0.21

Ask the moment Inhibrx Biosciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Inhibrx Biosciences, Inc. report Q1 2026 earnings?
Inhibrx Biosciences, Inc. (INBX) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Inhibrx Biosciences, Inc.'s Q1 2026 revenue and EPS?
Inhibrx Biosciences, Inc. reported diluted EPS of $-2.15 for Q1 2026.
Did Inhibrx Biosciences, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-2.37 by $0.22.
How did Inhibrx Biosciences, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 23.2% from $-2.80.
Where can I find Inhibrx Biosciences, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0002007919-26-000020) and the 10-Q periodic report (0002007919-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.